Alaunos Therapeutics

TCRT on Nasdaq. Market value $4m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 29 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

  • at least 20.0%
    (filed with 4 related holders)
    Since 13 October 2026
    What they said

    The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of September 30, 2026, plus the shares of Common Stock issued in the Financing (as defined below). The Reporting Persons' securities include (i) 687,789…

    Read the filing
  • WaterMill Asset Management Corp.
    at least 10.0%+1.0 pts
    (filed with 1 related holder)
    Since 13 October 2026
  • Price Adrian
    at least 8.6%0.0 pts
    (filed with 20 related holders)
    Since 24 February 2026
    What they said

    On February 24, 2026, counsel for Adrian Price sent a letter on behalf of the Reporting Persons to counsel of Alaunos Therapeutics, Inc. (the "Company"), and requested that the Company's counsel provide the letter to the Company's Board of Directors ("Board"). In this letter,…

    Read the filing
  • Hexagon ONE Inc
    Activist
    Wants board seats
    Sold down below 5%
    Since 24 February 2026
    What they said

    On February 24, 2026, counsel for Adrian Price sent a letter on behalf of the Reporting Persons to counsel of Alaunos Therapeutics, Inc. (the "Company"), and requested that the Company's counsel provide the letter to the Company's Board of Directors ("Board"). In this letter,…

    Read the filing
  • Strategic EP, LLC
    Passive investor
    Sold down below 5%
    Since 14 October 2025
  • PMGC CAPITAL LLC
    Passive investor
    Sold down below 5%
    Since 22 August 2025
    What they said

    Item 4 is hereby replaced in its entirety as follows: Between June 16, 2025 and August 22, 2025, PMGC LLC sold all of Common Stock of the Issuer on the open market at prices ranging between $1.92 to $4.53 (such sales, in the aggregate, the "Transactions"). As of August 25, 2025,…

    Read the filing
  • MSD Partners, L.P.
    Passive investor
    Sold down below 5%
    Since 31 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Alaunos Therapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 31 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 10 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at year end. Mistakes could slip into the numbers.

    “Based on that evaluation, our principal executive officer and principal financial officer has concluded that as of December 31, 2025, our disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting related to the lack of sufficient personnel to allow for the required segregation of duties.”
    Show the full paragraph
    Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer and our principal accounting officer, we have evaluated the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) or 15d-15(e) promulgated under the Exchange Act, as of December 31, 2025. Based on that evaluation, our principal executive officer and principal financial officer has concluded that as of December 31, 2025, our disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting related to the lack of sufficient personnel to allow for the required segregation of duties.

    From the 10-K filed 31 March 2026, Item 9A. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.